Business
Poster presentation of Imperial College data
Poster presentation of Imperial College data.
About this update from Theracryf Plc
[{"type":"text","content":"\n \nRNS Number : 2523U Evgen Pharma PLC 28 March 2019 \n\n \n\n\n\n\nFor immediate release\n\n\n28 March 2019\n\n\n\n\n \nRNS REACH\n \n \n \n \n \n \nEvgen Pharma plc \n (\"Evgen\" or \"the Company\")\n \nPoster presentation from research collaboration with Imperial College London\nEvgen Pharma (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, is pleased to announce that mechanistic data from the Company's research collaboration with Imperial College London (''Imperial'') are today being presented in a poster at the ABPP (\"Activity-Based Protein Profiling\") 2019 symposium in Belgium. \nImperial's research work provides further insight into the potential mechanism of action of SFX-01 in metastatic breast cancer and identifies potential biomarkers for determining the efficacy of SFX-01 in this indication.\nThe poster can be viewed via this link http://www.evgen.com/pipeline/\nEvgen's on-going collaboration with Imperial, funded principally by an Engineering and Physical Sciences Research Council Impact Acceleration Account grant, uses advanced chemical proteomics technology to identify targets for SFX-01 and also to identify potential biomarkers associated with efficacy in metastatic breast cancer and other diseases.\nEarlier this week, Evgen announced its first Phase II clinical read-out of SFX-01 in metastatic breast cancer. The headline data showed that SFX-01 had met its primary safety and efficacy endpoints in the STEM open label study, marking a highly significant step in the product's clinical development. \n \nSteve Franklin, CEO of Evgen Pharma, said:\n''We are delighted that our collaboration with Professor Tate and Imperial College is already yielding results that will support and inform the development of SFX-01 in metastatic breast cancer and other diseases. Having announced positive Phase II clinical data in this indication earlier this week, it is particularly interesting to see results that may ultimately lead to one or more biomarkers that could potentially be used to help identify those patients that would be expected to have a better response to SFX-01.''\n \nEnquiries:\n \n\n\n\n\nEvgen Pharma plc\nDr Stephen Franklin, CEO\nRichard Moulson, CFO\nwww.evg...